WT1 and glioblastoma: Silencing of WT1 causes decreased proliferation and viability in most cancer cell lines including K562 and MM6 leukemia [69], MCF-7 breast cancer [48]–[49], A549 lung cancer [50], B16F10 melanoma lung metastasis [51], and U251MG human multiform glioblastoma [53].